Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTern Regulatory News (TERN)

Share Price Information for Tern (TERN)

Share Price is delayed by 15 minutes
Get Live Data
1.20    -0.11 (-8.40%)
Bid:
1.10
Ask:
1.30
Spread: 0.20 (18.182%)
Market Cap: £10.27m
TERN Live PriceLast checked at - London Stock Exchange

Intraday Tern Share Chart

Tern PLC: Additional Investment in FundamentalVR

30 Oct 2018 07:01

Tern PLC (TERN) Tern PLC: Additional Investment in FundamentalVR 30-Oct-2018 / 07:00 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.


30 October 2018

Tern Plc ("Tern" or the "Company")

Additional Investment in FundamentalVR

Tern Plc (AIM: TERN), the investment company specialising in the Internet of Things ("IoT"), is pleased to announce that it has made a further £1.1 million investment in FVRVS Limited ("FundamentalVR" or "Fundamental"), a leading Virtual Reality ("VR") training and data analysis technology platform and one of its existing portfolio companies. Fundamental's award-winning platform combines immersive virtual reality with cutting-edge haptics (the sense of touch) to create low-cost and scalable 'flight simulator' experiences which offer a new way to facilitate skills development for surgeons. This additional investment increases Tern's holding in FundamentalVR from 18.3% to 34.7%.

This investment follows Fundamental's recent signing of a three year term joint development agreement with the Mayo Foundation for Medical Education and Research ("the Mayo Clinic"), the U.S. leading academic medical centre which was voted Best Hospital in 2018 U.S. News & World Report rankings of top hospitals in the USA, which will see the two parties collaborating on a range of simulation and education products with an initial focus on the General Surgery area. Additionally, the current release of the Fundamental Surgery platform is now live in the Mayo Clinic's world-renowned simulation centres located in Arizona, Florida and Minnesota.

This new alliance is expected to accelerate FundamentalVR's progress in building out its procedures portfolio and enables the FundamentalVR team to have access to leading surgical knowledge as well as 3D modelling, data scientists and simulation specialists at the Mayo Clinic. The Mayo Clinic and FundamentalVR are both ultimately focused on improving patient outcomes and share the belief that the comparative data insight and measurement collected and available through the FundamentalVR platform will have a profoundly positive impact on medical outcomes and products around the world.

Under the joint development agreement, the Mayo Clinic will receive royalties on the sale of jointly developed licensed products and will receive other consideration from FundamentalVR upon achieving certain milestones.

FundamentalVR's current revenues from its existing procedures and its pipeline of new procedures are expected to accelerate through the addition of new procedures and potential licencing areas emanating from this new partnership. Additionally, in the longer term FundamentalVR expects to build additional revenue sources from its data insight, accreditation and licensing of the development assets in complementary medical markets.

Based on FundamentalVR's latest statutory accounts for the year ended 31 December 2017, FundamentalVR had net assets of £886,019 and a loss for the year of £247,921.

Tern CEO, Al Sisto, said, "FundamentalVR has proven its agility to rapidly deliver on its strategy since our initial investment.  We are really pleased to provide this follow-on investment in this innovative company. They have an ambitious strategy, forward revenue visibility and now, a prestigious content partner that recognises the ability of their platform to revolutionise surgical training and ultimately, patient outcomes. We are pleased with their execution and the value it is creating in the business and therefore delighted to have increased our ownership position."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

**ENDS**

Enquiries

Tern plc

Al Sisto, CEO

Sarah Payne, Finance Director

 

Via Redleaf

 

Allenby Capital Limited

(Nomad and Joint broker)

David Worlidge/Alex Brearley

 

 

Tel: 0203 328 5656

 

Whitman Howard

(Joint broker)

Nick Lovering/Christopher Furness

 

 

Tel: 020 7659 1234

 

Redleaf Communications

PR

Elisabeth Cowell/ Fiona Norman

 

Tel: 020 3757 6880

 


ISIN:GB00BFPMV798
Category Code:MSCH
TIDM:TERN
LEI Code:2138005F87SODHL9CQ36
Sequence No.:6362
EQS News ID:739115
 
End of AnnouncementEQS News Service

UK Regulatory announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
8th Jun 20267:00 amRNSNotice of AGM
29th May 20265:00 pmRNSTotal Voting Rights
26th May 20267:00 amRNSInvestment in Talking Medicines CLNs
22nd May 20267:00 amRNSDevice Authority Convertible Loan Notes Investment
19th May 20267:00 amRNSPlacing to raise £222,000
12th May 20267:00 amRNS-RDevice Authority Strategic Partnership
8th May 202612:53 pmRNSResult of GM & Update on Open Offer
8th May 20267:00 amRNSResults of Open Offer
21st Apr 20267:00 amRNSOpen Offer and Notice of General Meeting
31st Mar 20265:00 pmRNSTotal Voting Rights
5th Mar 20267:00 amRNSExtension of loan facility agreement
3rd Mar 20267:00 amRNSResults of Open Offer
13th Feb 20267:00 amRNSOpen Offer at 0.40p to raise up to £384,408
5th Feb 20267:00 amRNS-RTern Notes Automotive Momentum at Device Authority
15th Jan 20267:00 amRNSUpdate regarding SVV2
8th Jan 20267:00 amRNSInvestor Presentations
23rd Dec 20257:00 amRNS-ROnline Investor Presentation and Q&A Session
23rd Dec 20257:00 amRNS-ROnline Investor Presentation and Q&A Session
12th Dec 20257:00 amRNSIssue of Talking Medicines Convertible Loan Notes
28th Nov 20257:00 amRNSUpdate regarding capital commitment to SVV2
25th Nov 20257:00 amRNSTalking Medicines CLN Modifications
31st Oct 20253:35 pmRNSTotal Voting Rights
15th Oct 20257:00 amRNSResults of Open Offer
9th Oct 20257:00 amRNSRemuneration Reductions & Distribution Commitment
29th Sep 20257:00 amRNSOpen Offer to raise up to £642,486
15th Sep 20257:00 amRNSExtension of Loan Facility Term
4th Sep 20257:00 amRNSInterim results for the six months to 30 June 2025
1st Sep 20257:00 amRNSAppointment of shareholder relations adviser
31st Jul 20254:34 pmRNSTotal Voting Rights
29th Jul 20257:00 amRNSResults of underwritten Open Offer & TVR
24th Jul 20257:00 amRNSReceipt of Bridging Loan
14th Jul 20257:00 amRNSUnderwritten Open Offer to raise £642,486
30th Jun 202512:07 pmRNSResult of AGM
13th Jun 20257:00 amRNSDirector Share Purchase
11th Jun 20257:00 amRNSDirector Share Purchase
6th Jun 20257:00 amRNSNotice of AGM and Director Retirement
5th Jun 20257:00 amRNSResults for the year ended 31 December 2024
30th May 20255:39 pmRNSTotal Voting Rights
7th May 20257:00 amRNSResults of Underwritten Open Offer
24th Apr 20257:00 amRNSPurple Transform appointment
17th Apr 20257:00 amRNSUnderwritten Open Offer to raise £340,140
11th Mar 20257:00 amRNS-RDevice Authority Microsoft & CyberArk Partnership
11th Mar 20257:00 amRNS-RSure Ventures Update
28th Feb 20255:00 pmRNSTotal Voting Rights
21st Feb 20257:00 amRNSPlacing to raise £221,154
14th Jan 20257:30 amRNS-RProgressive Equity Research Report
10th Jan 20257:00 amRNSInvestor Presentations
2nd Jan 20257:00 amRNSInvestment in Sure Ventures plc
31st Dec 20241:30 pmRNSTotal Voting Rights
23rd Dec 202411:39 amRNSDevice Authority update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.